Immune Therapeutics Inc. (OTCMKTS:IMUN)
Immune Therapeutics Inc. (OTCMKTS:IMUN) has signed a memorandum of understanding with GB Pharma Holdings and Rougier Pharma for the distribution of its Lodonal treatment in the Ivory Coast. The signing of the agreement comes on the heels of the company gaining marketing and distribution approval for the drug in Nigeria.
Lodonal Ivory Coast Distribution
The developer of the patented therapy for cancer, HIV, and autoimmune disease plans to finalize the agreement with its distribution partners over the next 60 to 90 days. Distribution and availability of the drug will proceed based upon the approval by the Directorate of Pharmacy and Medicines. The company expects distribution to begin by the end of the year.
Lodonal is an immunomodulation that has so far proven to be reliable in offsetting most of the side effects associated with ART therapy. The treatment works by rebalancing the immune system leading to a rebound of the endogenous opioids involved in regulating the immune function.
“This is our next step in making Lodonal available to millions of people in Africa and hopefully around the world that suffer from HIV. HIV therapy does not fully restore health. For reasons that remain to be elucidated, antiretroviral-treated HIV disease is now associated with a new constellation of problems, generally referred to as “non-AIDS morbidity,” said CEO, Noreen Griffin.
Immune Therapeutics Inc. (OTCMKTS:IMUN) plans to start exporting the treatment into Ivory Coast having been issued with the Certificate of Pharmaceutical Product. However, the company still has to submit a New Drug application which will include among other things information pertaining to COPP, Proof of cGMP, Dossier and Patient data sheet
Immune Therapeutics Inc. (OTCMKTS:IMUN) is positioning Lodonal as an immune booster for patients with cancer and HIV/AIDS within the Pharmacies de la Santé Publique (PSP) in Ivory Coast.
Immune Therapeutics Inc. (OTCMKTS:IMUN) has gained regulatory approval for the marketing of Lodonal in Nigeria. The approval is considered by some experts to be an endorsement for the breakthrough therapy that has proved to be reliable in improving the quality of life for patients with life-threatening diseases.
In addition to the Ivory Coast and Nigeria milestone achievements, the pharmaceutical company has also submitted a New Drug Application to the Pharmacy and Poison Board in Kenya for Lodonal. Approval in Kenya should go a long way in expanding the target market for the novel treatment.
Immune Therapeutics Inc. (OTCMKTS:IMUN) stock was up by 1.7% in Wednesday’s trading session, ending the day at $0.0599 a share
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
About the author: Jane started her Wall St career out of graduate school, working for a mid-size investment bank as an analyst covering commodities. After several years working with global mining firms, she began her own investment relations business and sold it in 2007. Jane is now retired and lives in New England but enjoys researching new companies and trends.